# Introducing Parallel Search Turbo: the fastest and lowest-cost search for AI

HumanMachine

Life Sciences

## Track every drug, regulation, and competitor in your space

Track every drug, trial, regulation, and competitor automatically, with structured, cited intelligence pulled from registries and filings in real time.

### Monitor clinical trial registries and FDA updates for my target and indication.

- New Phase 2 trial posted for a GLP-1 analog  
  clinicaltrials.gov  
  5M AGO  
- FDA grants Fast Track to a KRAS inhibitor  
  fda.gov  
  1H AGO  
- Competitor reports positive Phase 3 topline  
  businesswire.com  
  5H AGO

### Use Cases

## Research the whole drug landscape

Map, monitor, and mine the science behind every decision

### Map a drug or target's competitive landscape

Give it a therapeutic area, target, or mechanism. Get back approved and investigational assets, the companies behind them, clinical status, and the investors active in the space, as a structured, cited output.

Map the KRAS G12D inhibitor landscape: assets, the companies behind them, and clinic status.

| # | ASSET       | COMPANY               | PHASE     |
|---|-------------|----------------------|-----------|
| 1 | NVX-301    | Helix Bio            | Phase 2   |
| 2 | AR-2207    | Aravon Therapeutics   | Phase 1   |
| 3 | BLT-19     | Beacon Lead Tx       | Preclinical |
| 4 | SLB-9      | Solace Bio           | Phase 1   |

### Monitor pipelines, trials, and approvals

Watch the drugs, programs, and competitors you care about: trial readouts, phase transitions, FDA and EMA approvals, guidance, and commercialization events, with alerts the moment something material changes.

Watch NVX-301 and the KRAS G12D set: trial readouts, phase transitions, and FDA/EMA approvals.

| MONITOR                                          |
|-------------------------------------------------|  
| Phase 2 readout, NVX-301 (Helix Bio)  
| 5M AGO  
| clinicaltrials.gov  
| Accelerated approval, AR-2207  
| 1H AGO  
| fda.gov  
| CHMP positive opinion, BLT-19  
| 5H AGO  
| ema.europa.eu

### Mine scientific literature and clinical data

Pull clean, structured data out of papers, trial registries, and regulatory filings, including efficacy, mechanism of action, endpoints, and real-world evidence.

CLINICAL DATA

- NVX-301 · Phase 2  
- MECHANISM: KRAS G12D inhibitor  
- INDICATION: Metastatic colorectal cancer  
- ENROLLMENT: 248  
- PRIMARY ENDPOINT: ORR 41% (95% CI 34–48)

### Discover licensing and M&A targets

Describe your criteria in plain language and get back a live list of assets or companies, including the long tail of private biotechs that never make it onto traditional databases.

| # | COMPANY            | LEAD ASSET  | PHASE   | MATCH     |
|---|-------------------|-------------|---------|-----------|
| 1 | Northwind Bio     | NVX-301     | Phase 2 |           |
| 2 | Aravon Therapeutics| ARV-118     | Phase 1 |           |
| 3 | Solace Bio        | SLB-9       | Phase 1 |           |
| 4 | Kestrel Bio       | KST-2       | Phase 1 |           |

## Customer Stories

### Formation Bio runs its drug-development funnel on Parallel

Formation Bio monitors tens of thousands of drug programs daily, auto-enriches the ones that matter, and commissions deep research on priority assets to inform valuation.

### Convoke mines the biopharma literature at research-grade precision

The biopharma AI company runs deep research and monitoring over scientific publications, trials, and regulatory sources – Work that demands exact publication dates and traceable citations.

"Parallel provided us with a big upgrade in speed and index coverage. Combined with a 5x improvement in cost efficiency, it was an easy decision to build our agents with them."

Vikas Velagapudi, Founder, Convoke

## Trust

### Built for enterprise, secure by design

Every Parallel output includes the [Basis framework](https://docs.parallel.ai/task-api/guides/access-research-basis), unique to Parallel: calibrated confidence scores, citations, source excerpts, and reasoning traces.

- SOC 2 Type 2
- Zero data retention Available
- HIPAA-ready offering
- GDPR Compliance
- Single sign-on (SSO/SAML)

## FAQs

- **Can Parallel monitor clinical trial registries automatically?**
  Yes. The [Monitor API](https://docs.parallel.ai/monitor-api/monitor-quickstart) watches ClinicalTrials.gov, FDA, and EMA sources for phase transitions, readouts, and approvals — alerting the moment something material changes on the drugs and programs you care about.

- **How does Parallel help map a drug's competitive landscape?**
  Give Parallel a therapeutic area, target, or mechanism. [FindAll](https://docs.parallel.ai/findall-api/findall-quickstart) and [Task](https://docs.parallel.ai/task-api/task-quickstart) return approved and investigational assets, the companies behind them, clinical status, and active investors — as a structured, cited output.

- **Does Parallel cover FDA and EMA regulatory data?**
  Yes. Parallel reads regulatory filings and announcements continuously, including FDA Fast Track designations and EMA CHMP opinions, alongside trial registries and scientific literature — with citations on every claim.

- **Can I use Parallel for biotech licensing or M&A target discovery?**
  Yes. Describe your criteria in plain language and [FindAll](https://docs.parallel.ai/findall-api/findall-quickstart) returns a live list of assets or companies — including the long tail of private, clinical-stage biotechs that never appear on traditional databases.